Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | TAS2R38 | P59533 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19560711 | 0.83 | MEN1 (0.37) | ALDH1A1TDP1 | |
| SCHEMBL11429636 | 0.80 | — | — | |
| SCHEMBL19646891 | 0.75 | — | — | |
| SCHEMBL10596832 | 0.75 | CRBN (0.38) | ALDH1A1TDP1CRBNTAS2R38 | |
| SCHEMBL7723727 | 0.74 | KDM4E (0.33) | ALDH1A1TDP1CRBNTAS2R38 | |
| SCHEMBL7723729 | 0.74 | KDM4E (0.33) | ALDH1A1TDP1CRBNTAS2R38 | |
| SCHEMBL27355778 | 0.74 | KMT2A (0.38) | ALDH1A1 | |
| SCHEMBL23745122 | 0.73 | ALDH1A1 (0.36) | ALDH1A1TDP1CRBNTAS2R38 | |
| SCHEMBL14724921 | 0.73 | CRBN (0.32) | ALDH1A1TDP1CRBNTAS2R38 | |
| SCHEMBL24276896 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3950682-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | Shanghai Synergy Pharmaceutical Sciences Co., Ltd (CN) | 2022-02-09 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2020192652-A1 | PREPARATION METHOD FOR AMIDE COMPOUNDS AND USE THEREOF IN MEDICAL FIELD | 上海华汇拓医药科技有限公司 | 2020-10-01 | — | — | WO | disclosed |
| US-10682418-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2020-06-16 | — | — | US | disclosed |
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS | 2018-02-15 | — | — | US | disclosed |
| US-9827326-B2 | Polymer-sunitinib conjugates | NEKTAR THERAPEUTICS (US) | 2017-11-28 | — | — | US | disclosed |
| EP-2654799-B1 | POLYMER-SUNITINIB CONJUGATES | NEKTAR THERAPEUTICS (US) | 2017-11-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180043028-A1 | POLYMER-SUNITINIB CONJUGATES | FLT4, TEK, TIE1 | ALDH1A1 3150/4885TDP1 2516/4885CRBN 1335/4885 |
| US-10682418-B2 | Polymer-sunitinib conjugates | FLT4, TEK, TIE1 | ALDH1A1 3150/4885TDP1 2516/4885CRBN 1335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.